Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Melanoma × Mesna × Clear all

Phase

Status

Active not recruiting 2 Withdrawn 1 Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Myelodysplastic Syndromes 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Lymphoma 1 Leukemia, Myeloid, Acute 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Biphenotypic, Acute 1 Leukemia 1 Hodgkin Disease 1 Fibrolamellar hepatocellular carcinoma 1 Carcinoma, Hepatocellular 1 Blast Crisis 1

Interventions

Nivolumab 17 Ipilimumab 14 pembrolizumab 11 Cyclophosphamide 8 trametinib 7 dabrafenib 6 Interleukin-2 6 aldesleukin 5 Vemurafenib 5 Radiotherapy 5 sargramostim 4 130-nm albumin-bound paclitaxel 4 fludarabine 3 Specimen Handling 3 Radiosurgery 3 Melphalan 3 Granulocyte-Macrophage Colony-Stimulating Factor 3 fludarabine phosphate 2 encorafenib 2 binimetinib 2 Magnetic Resonance Spectroscopy 2 Introns 2 Infliximab 2 Celecoxib 2 CTLA-4 Antigen 2 Biopsy 2 Bevacizumab 2 Albumin-Bound Paclitaxel 2 yeast-CEA vaccine 1 vitespin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06190249 2025-06-05

LN-144

Case Comprehensive Cancer Center

Phase 1 Withdrawn

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡